Sanofi experiences mixed victories with its bispecific Lunsekimig in phase two studies, performing well in asthma and rhinosinusitis, but failing as an eczema treatment. The company continues to make deals to further innovation, entering partnerships with Pfizer and Kali Therapeutics for vaccines and autoimmune disease treatments respectively. In a major leadership shakeup, Sanofi replaces CEO Paul Hudson amid stalled turnaround efforts, appointing exiting Merck KGaA head Belén Garijo. The company remains undeterred by failed attempts in certain areas, scrapping plans for an mRNA seasonal flu vaccine and continuing to value long-term innovation and growth as a leading multinational pharmaceutical company. Nonetheless, Sanofi faces various financial and legal challenges, including a suit from Texas alleging provider bribery and recent share price weakness. Despite these hurdles, Sanofi forges ahead with strategic acquisitions and global licensing deals.
Sanofi News Analytics from Mon, 15 Dec 2025 08:00:00 GMT to Sat, 11 Apr 2026 06:16:43 GMT - Rating 1 - Innovation 6 - Information 7 - Rumor -2
